

PREVENTION OF ALZHEIMER'S DISEASE – WHAT WOULD IT TAKE?

Michael Krams

Janssen Pharmaceuticals, Titusville, NJ/USA

There is a time lag of years, may be decades before the initial occurrence of histopathological hallmarks of Alzheimer's disease is followed by clinical manifestations of the disease. This begs the question when to initiate pharmacological interventions aiming at modifying the underlying disease: should we treat or should we prevent?

In this session we will discuss how to make Alzheimer Prevention trials a mainstream effort in the clinical development of disease modifying treatments against Alzheimer's disease:

- The underlying biology: Which targets are of interest?
- The patient population: Whom to select and how?
- The endpoint: How to observe? A GPS system built of biomarker satellites.
- The clinical trial methodology: A cross between epidemiological natural history study and a pharmacological intervention trial
- The political and regulatory landscape: Educating the environment

Experts from different backgrounds (neuroscience, medicine, epidemiology, statistics and drug development) will present a short position statement, followed by a structured debate with an ambition to identify solutions on how to make prevention trials happen.